A small study recently found that the experimental drug nemolizumab (Mitchga) substantially improved itching in people with atopic dermatitis (AD). These improvements, in turn, were associated with ...

If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world population ...

Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life. Casey Butrus, PharmD: Dr Cameron, what’s the typical onset of action when you’re looking at a ...

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab's fast onset of ...

Please provide your email address to receive an email when new articles are posted on . Tapinarof cream 1% showed low discontinuation rates. The cream has no restriction of use. Tapinarof patients ...

Please provide your email address to receive an email when new articles are posted on . Eight of 10 participants reported an itch reduction score of 4 points by week 8. All participants reported a ...

More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...

While other triggers are more likely to bring on an atopic dermatitis flare, Megan Rogge, MD, of UT Health in Houston talks about when to consider food allergies and recommend an elimination diet.

Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...

Also called eczema, atopic dermatitis is characterized by itchy, flaky, scaly skin, and it can happen on any part of the body, including the face. Although symptoms like these can be disruptive ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...